Production & Manufacturing

Florida Biologix helps Taiwan University Hospital achieve manufacturing objectives

PBR Staff Writer Published 17 May 2012

Florida Biologix has produced, purified and tested a clinical batch of novel gene therapy for use in a Phase I trial of AADC deficiency, led by Paul Wuh-Liang Hwu.

Florida Biologix provided cGMP manufacturing services under a contract signed in March 2008, to National Taiwan University Hospital.

Florida Biologix director and publication co-author Richard Snyder said the company's specialized experience in the manufacture, testing and filling of biopharmaceuticals combined with business model made it an ideal partner to work with the National Taiwan University Hospital.

"As with all of our clients, we worked closely with their team to achieve their manufacturing objectives," Snyder added.

Florida Biologix is a Phase I/II biologics contract development, manufacturing and testing organization.